In August 2020, Global Outbreak and Alert and Response Network (GOARN) sent a request for assistance for epidemiologists to be deployed to the Democratic Republic of the Congo (DRC) to support the Ebola virus disease (EVD) outbreak response in the Equateur Province.
ECDC coordinates the enhanced surveillance for hepatitis A, B and C to help countries define epidemiological trends or transmission patterns among newly diagnosed cases.
World Hepatitis Day on 28 July provides an opportunity each year to increase the awareness and understanding of viral hepatitis.
European Testing Week is a European campaign that encourages partner organisations, in community, health care and policy institutions, throughout Europe to unite for one week twice a year to increase testing efforts and promote awareness on the benefits of earlier hepatitis and HIV testing.
On the way towards the Sustainable Development Goal (SDG) for health, Europe has one important battle to take on: reducing the proportion of those living with undiagnosed HIV and viral hepatitis. Current status in the EU/EEA: one in seven people living with HIV are unaware of their infection, up to four out of 5 people living with hepatitis B and three out of four people with hepatitis C infection have not yet been diagnosed.
Two out of the four drugs tested in a multi-drug randomised control trial have been found more effective in treating Ebola, the World Health Organization announced on Monday. The Data and Safety Monitoring Board, an independent body that has been reviewing interim safety and efficacy data, has therefore recommended that the study be stopped and that all future patients be randomized to receive either REGN-EB3 or mAb114, in what is being considered an extension phase of the study.